Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy

Inhibitory antibodies to factor VIII (FVIII) are a major complication in the treatment of hemophilia A, affecting approximately 20% to 30% of patients. Current treatment for inhibitors is based on long-term, daily injections of large amounts of FVIII protein. Liver-directed gene therapy has been use...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Finn, Jonathan D., Ozelo, Margareth C., Sabatino, Denise E., Franck, Helen W. G., Merricks, Elizabeth P., Crudele, Julie M., Zhou, Shangzhen, Kazazian, Haig H., Lillicrap, David, Nichols, Timothy C., Arruda, Valder R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2010
Gaiak:
Gene Therapy
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3031380/
https://ncbi.nlm.nih.gov/pubmed/20876851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-06-288001
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak